Cytomegalovirus Infections: all 362 studies
Page 3 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.
- Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / EndotheliitisCompletedNCT02943057Phase 4
- Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological StudyTerminatedNCT02843880
- Biochip for HCMV Detection in Breast MilkTerminatedNCT02840825
- Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMVCompletedNCT02798692Phase 1
- Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) InfectionStatus unknownNCT02787382Phase 3
- Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant RecipientsCompletedNCT02784756Not applicable
- Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMVCompletedNCT02782988
- Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ TransplantationStatus unknownNCT02779439Phase 1
- A Retrospective Chart Review Study of Gene-Eden-VIR/NovirinCompletedNCT02715752
- A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in ChinaCompletedNCT02710864
- Virus-specific ImmunoTherapy Following Allogeneic Stem Cell TransplantationWithdrawnNCT02702427Phase 1/2
- Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative ColitisCompletedNCT02684734
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant PatientsCompletedNCT02683291Phase 4
- Screening for Congenital Cytomegalovirus Infection in NewbornsCompletedNCT02683096
- Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care UnitCompletedNCT02680743Not applicable
- Conversion to Sirolimus: Effects in Cytomegalovirus Infection RecurrenceStatus unknownNCT02671318Phase 4
- A Cohort Study of Congenital Cytomegalovirus Infection Among Pregnant Women and Their Newborns in ChinaCompletedNCT02645396
- The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen UniversityCompletedNCT02642822
- Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and BalanceTerminatedNCT02606266Phase 2/3
- Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)TherapyCompletedNCT02600065
- Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA VaccineWithdrawnNCT02594566Phase 1
- Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney TransplantCompletedNCT02550639Phase 4
- Cell-mediated Immunity for Prevention of CMV DiseaseCompletedNCT02538172Not applicable
- Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in ChinaStatus unknownNCT02456610Phase 1
- Safety and PK of MBX-400 (Cyclopropavir) in Normal VolunteersCompletedNCT02454699Phase 1
- Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative ColitisCompletedNCT02439372
- Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During PregnancyCompletedNCT02351102Phase 2/3
- Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) InfectionWithdrawnNCT02346617Phase 1/2
- Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine ACompletedNCT02328963Phase 4
- CMV Intensive Care UnitsCompletedNCT02324244
- Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)CompletedNCT02313857Phase 1
- Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus InfectionActive, not recruitingNCT02210078Phase 2
- Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT RecipientsCompletedNCT02156479
- Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing ScreeningCompletedNCT02139423Not applicable
- Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in PregnancyStatus unknownNCT02129465
- An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis PatientsCompletedNCT02103426Phase 1
- Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal TransplantCompletedNCT02084446Phase 4
- MSC for Treatment of CMV InfectionStatus unknownNCT02083731Phase 2
- Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)CompletedNCT02081716
- Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positiveCompletedNCT02076971
- A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.CompletedNCT02067169
- Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant RecipientsCompletedNCT02025335
- Congenital Cytomegalovirus: Efficacy of Antiviral TreatmentCompletedNCT02005822Phase 3
- Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)No longer availableNCT01945619
- Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to CytomegalovirusCompletedNCT01941056Phase 1
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant RecipientsStatus unknownNCT01927588Phase 4
- Prognostic Value of Neonatal Markers for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus in UteroCompletedNCT01923636Not applicable
- Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant RecipientsCompletedNCT01833416
- Clinical Trial of Behavioral Modification to Prevent Congenital CytomegalovirusCompletedNCT01819519Not applicable
- A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft RecipientsCompletedNCT01753167Phase 2
- Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus InfectionStatus unknownNCT01659684Not applicable
- Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled TrialTerminatedNCT01655212Phase 3
- In Utero Treatment of Cytomegalovirus congénitale Infection With ValacyclovirCompletedNCT01651585Phase 4
- CMV Modulation of the Immune System in ANCA-associated VasculitisStatus unknownNCT01633476Phase 2
- Safety Study of Human Anti-Cytomegalovirus Monoclonal AntibodyCompletedNCT01594437Phase 1
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Cut Off for the Diagnosis of Cytomegalovirus (CMV) Disease in Serum-positive Kidney Transplant RecipientsCompletedNCT01573039
- Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMVCompletedNCT01535885Phase 1
- Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant RecipientsStatus unknownNCT01473849
- Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium MycophenolateCompletedNCT01354301Phase 4
- Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus InfectionStatus unknownNCT01353053
- Injection of CD4 and CD8 + T Cells Anti-Cytomegalovirus (CMV) or Anti-adenovirusCompletedNCT01325636Phase 1/2
- Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCTTerminatedNCT01274377Phase 1
- Alternate Donor Study of Pre-Emptive Cellular TherapyCompletedNCT01220895Phase 2
- Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
- Clinical Evaluation of Ultrashort-term Heat Inactivation of Cytomegalovirus (CMV) Containing Raw Breast Milk to Prevent CMV-infection of Preterm InfantsCompletedNCT01178905Not applicable
- A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of AgeCompletedNCT01165580Phase 1
- Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.WithdrawnNCT01151462
- The Link Between Human Cytomegalovirus (HCMV) and HypertensionStatus unknownNCT01113359
- The Maternal Cellular Immune System and Cytomegalovirus Intrauterine InfectionStatus unknownNCT01081379
- Cytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy StudyCompletedNCT01077908Phase 3
- Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)CompletedNCT01070797Phase 1
- In UTERO Treatment of Cytomegalovirus Congenital Infection With ValacyclovirTerminatedNCT01037712Phase 4
- T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell TransplantStatus unknownNCT00986557Phase 2
- Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus TherapyStatus unknownNCT00966836Phase 3
- Determining a Viral Load Threshold for Treating Cytomegalovirus (CMV)CompletedNCT00947141Phase 4
- TT-CMV Observational Birth Cohort StudyCompletedNCT00907686
- Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV InfectionCompletedNCT00881517Phase 2/3
- Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and AdenovirusCompletedNCT00880789Phase 1
- Does Normal Brain Imaging Predict Normal Neurodevelopmental Outcome in Fetuses With Proven Cytomegalovirus Infection?CompletedNCT00872703
- Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant PatientsStatus unknownNCT00828503Phase 2
- Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant RecipientsCompletedNCT00817908
- Cytomegalovirus Cell-Mediated ImmunityCompletedNCT00815165
- Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus InfectionsStatus unknownNCT00769613Phase 1
- Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant PatientsCompletedNCT00730769Phase 4
- Measuring Changes in Blood in Patients at High Risk of Cytomegalovirus Infection After Undergoing Donor Bone Marrow Transplant or Peripheral Blood Stem Cell TransplantCompletedNCT00716911Not applicable
- Immune Response and Cytomegalovirus in Intensive Care Unit (ICU) PatientsCompletedNCT00699868Not applicable
- Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion CorrelatesCompletedNCT00677482
- Trial of Donor T Cells Sensitized With Pentadecapeptides of the CMV-PP65 Protein for the Treatment of Cytomegalovirus (CMV) Infections Following Allogeneic Hematopoietic Stem Cell TransplantsCompletedNCT00674648Phase 1
- Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell TransplantsCompletedNCT00673868Phase 1
- The Influence of Intensive Education and Coaching on Compliance for Oral Ganciclovir in the Prophylaxis of CMV: an Open Randomised TrialCompletedNCT00566072Not applicable
- Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV InfectionNo longer availableNCT00547235
- Influence of Persistent CMV-infection on Immune SenescenceCompletedNCT00461695Phase 4
- A Clinical Trial of an Alphavirus Replicon Vaccine for Cytomegalovirus (CMV)CompletedNCT00439803Phase 1
- Cell Mediated Immunity and the Prediction of CMV Infection In Solid Organ Transplant RecipientsCompletedNCT00436384
- Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult SubjectsCompletedNCT00435396Phase 1
- VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant RecipientsCompletedNCT00431353Phase 4
- Efficacy and Safety of Valcyte® as an add-on Therapy in Patients With Malignant Glioblastoma and Cytomegalovirus (CMV) InfectionCompletedNCT00400322Not applicable
- TAMOVALCIR in Allogenic Hematopoietic Progenitors TransplantCompletedNCT00386412Phase 2
- Study of Prophylactic Vs Preemptive ValganciclovirCompletedNCT00374686Not applicable